198 related articles for article (PubMed ID: 37220607)
1. Clinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy.
Kikushige Y
Blood Cell Ther; 2022 Dec; 5(Spec Edition):S1-S5. PubMed ID: 37220607
[TBL] [Abstract][Full Text] [Related]
2. [TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in human acute myeloid leukemia].
Sakoda T; Kikushige Y
Rinsho Ketsueki; 2023; 64(6):547-552. PubMed ID: 37407480
[TBL] [Abstract][Full Text] [Related]
3. [A TIM-3/galectin-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemia progression].
Kikushige Y
Rinsho Ketsueki; 2016 Apr; 57(4):412-6. PubMed ID: 27169443
[TBL] [Abstract][Full Text] [Related]
4. A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.
Kikushige Y; Miyamoto T; Yuda J; Jabbarzadeh-Tabrizi S; Shima T; Takayanagi S; Niiro H; Yurino A; Miyawaki K; Takenaka K; Iwasaki H; Akashi K
Cell Stem Cell; 2015 Sep; 17(3):341-52. PubMed ID: 26279267
[TBL] [Abstract][Full Text] [Related]
5. TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in acute myeloid leukemia.
Sakoda T; Kikushige Y; Miyamoto T; Irifune H; Harada T; Hatakeyama K; Kunisaki Y; Kato K; Akashi K
Blood Adv; 2023 May; 7(10):2053-2065. PubMed ID: 36745103
[TBL] [Abstract][Full Text] [Related]
6. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
[TBL] [Abstract][Full Text] [Related]
8. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
[TBL] [Abstract][Full Text] [Related]
9. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
Kikushige Y; Miyamoto T
Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
Wang J; Yang L; Dao FT; Wang YZ; Chang Y; Xu N; Chen WM; Jiang Q; Jiang H; Liu YR; Qin YZ
Leuk Lymphoma; 2022 Jan; 63(1):152-161. PubMed ID: 34405769
[TBL] [Abstract][Full Text] [Related]
11. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells.
Lee WS; Ye Z; Cheung AMS; Goh YPS; Oh HLJ; Rajarethinam R; Yeo SP; Soh MK; Chan EHL; Tan LK; Tan SY; Chuah C; Chng WJ; Connolly JE; Wang CI
Mol Cancer Ther; 2021 Sep; 20(9):1702-1712. PubMed ID: 34158344
[TBL] [Abstract][Full Text] [Related]
12. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
[TBL] [Abstract][Full Text] [Related]
13. TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways.
Kikushige Y
Cancer Sci; 2021 Sep; 112(9):3419-3426. PubMed ID: 34159709
[TBL] [Abstract][Full Text] [Related]
14. Live kinase B1 maintains CD34
Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes of CD34
Zahran AM; Aly SS; Rayan A; El-Badawy O; Fattah MA; Ali AM; ElBadre HM; Hetta HF
Oncotarget; 2018 Sep; 9(75):34056-34065. PubMed ID: 30344921
[TBL] [Abstract][Full Text] [Related]
16. Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
Martiáñez Canales T; de Leeuw DC; Vermue E; Ossenkoppele GJ; Smit L
Cancers (Basel); 2017 Jun; 9(7):. PubMed ID: 28665351
[TBL] [Abstract][Full Text] [Related]
17. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells.
Jaddaoui S; Bencharef H; Lamchahab M; Quessar A; Oukkache B
Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704721
[TBL] [Abstract][Full Text] [Related]
20. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
Sachs K; Sarver AL; Noble-Orcutt KE; LaRue RS; Antony ML; Chang D; Lee Y; Navis CM; Hillesheim AL; Nykaza IR; Ha NA; Hansen CJ; Karadag FK; Bergerson RJ; Verneris MR; Meredith MM; Schomaker ML; Linden MA; Myers CL; Largaespada DA; Sachs Z
Cancer Res; 2020 Feb; 80(3):458-470. PubMed ID: 31784425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
